Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955458 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| SCHEMBL88415 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| SCHEMBL5854141 | 0.83 | ADRA2C (0.48) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| Water SCHEMBL8939878 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| SCHEMBL3730543 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| Ethylene SCHEMBL173231 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| SCHEMBL3744643 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| SCHEMBL12227223 | 0.81 | KDM4E (0.64) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| SCHEMBL9625908 | 0.81 | KDM4E (0.69) | ALDH1A1KDM4EADRA2CHTR1AADRA2A | |
| SCHEMBL1913608 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4EADRA2CHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5380654-A | Process for the preparation of epoxides of means of microorganisms | JAPAN ENERGY CORPORATION (JP) | 1995-01-10 | — | — | US | disclosed |
| US-5376539-A | Aerobic incubation of allyl phenyl ether with arthrobacter, brevibacterium, corynebacterium, pseudomonas or rhodococcus yields glycidyl phenyl ether | NIPPON MINING CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| US-4188323-A | B-ADRENOLYTIC, VASODILATOR | A. MENARINI S.A.S. (IT) | 1980-02-12 | — | — | US | disclosed |
| US-4188323-A | B-ADRENOLYTIC, VASODILATOR | A. MENARINI S.A.S. (IT) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH1A1 412/4885KDM4E 4578/4885ADRA2C 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.